Modified AAV Capsid Peptide Targeting Brain Endothelium
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in delivering therapeutic agents to the central nervous system, particularly for treating lysosomal storage diseases, as proteins and enzymes struggle to cross the blood-brain barrier or achieve wide distribution within the brain.
Innovation Solution
Development of modified adeno-associated virus (AAV) capsid proteins with targeting peptides that preferentially bind to brain vascular endothelium, allowing for the redirection of viral vectors to brain tissue, enabling the delivery of therapeutic agents such as β-glucuronidase and other enzymes to the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional gene therapy methods are used to deliver therapeutic agents to the central nervous system, then the delivery system is simple, but the therapeutic agents cannot cross the blood-brain barrier or achieve wide distribution within the brain
Solution Approach 1:
The patent applies local quality by modifying specific regions of the AAV capsid protein to include cell-type-specific peptide sequences. These localized peptide modifications enable the viral vector to recognize and bind to specific receptors on brain vascular endothelial cells, while the rest of the capsid structure remains intact to maintain overall viral function and packaging capacity.
Solution Approach 2:
The patent uses peptide sequences as intermediary elements that mediate between the viral vector and the target brain vascular endothelial cells. These peptide intermediaries act as molecular bridges that facilitate specific binding to endothelial cell receptors, enabling the therapeutic agent to cross the blood-brain barrier through the endothelial cells.
2Ease of operation
If proteins are delivered intravenously to treat lysosomal storage diseases, then the delivery method is simple, but the proteins do not cross the blood-brain barrier
Solution Approach 1:
The patent creates a composite delivery system by combining the AAV viral vector structure with cell-type-specific peptide sequences. This composite capsid protein integrates the advantages of viral vectors (protective packaging, efficient cellular uptake) with the targeting specificity of peptides, forming a hybrid structure that can navigate the bloodstream and specifically target brain vascular endothelium.
3Reliability
If direct injection of DNA into brain tissue is performed, then the gene transfer efficiency is high, but the procedure is invasive and complex
Solution Approach 1:
The patent enables self-service by designing the AAV vector to autonomously navigate to the target tissue through built-in peptide targeting sequences. The viral vector self-directs to brain vascular endothelial cells via specific peptide-receptor interactions, eliminating the need for complex surgical procedures or external guidance systems while maintaining high gene transfer efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively rescues CNS deficits in animal models of lysosomal storage diseases by facilitating the secretion of therapeutic enzymes from vascular endothelial cells, leading to broad dissemination and correction of neuropathology across the brain, thereby improving behavioral and histological outcomes.
Implementation Method 1
peptides that function to target agents, such as viral vectors, to vascular endothelial cells of the central nervous system
Data Source
Figure 1A~1B
Figure 2A
Figure 2B
AI summary
The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain.